1. Offering routine trichomonas vaginalis testing to patients presenting for abortion at an urban hospital-based clinic
- Author
-
Morgan L. Cheeks, Stephanie Cohen, Dominika Seidman, Rebecca Schwartz, Elizabeth C Oleson, and Eleanor A. Drey
- Subjects
medicine.medical_specialty ,Trichomonas ,Sexually Transmitted Diseases ,Trichomonas Infections ,Abortion ,medicine.disease_cause ,Ambulatory Care Facilities ,Asymptomatic ,Article ,03 medical and health sciences ,Hospitals, Urban ,0302 clinical medicine ,Pregnancy ,Prevalence ,Trichomonas vaginalis ,medicine ,Humans ,030212 general & internal medicine ,030219 obstetrics & reproductive medicine ,biology ,Obstetrics ,business.industry ,Obstetrics and Gynecology ,biology.organism_classification ,Disease control ,Health equity ,Reproductive Medicine ,Female ,Trichomonas Screening ,medicine.symptom ,Trichomonas Vaginitis ,business ,Urban hospital - Abstract
Introduction The Centers for Disease Control and Prevention recommend considering screening asymptomatic women for trichomonas in high-prevalence settings. Whether urban abortion clinics constitute such a setting is unknown. Material and Methods We offered trichomonas screening to patients presenting for abortion from October 2018 to February 2019 as a practice improvement and conducted a chart review. Results Ninety-two percent (593/644) of patients underwent testing. Trichomonas prevalence was 10.0% (95% CI 7.7−12.6). Ninety five percent of patients diagnosed were treated. Testing only symptomatic patients would have missed 98% of infections. Conclusions Trichomonas was highly prevalent, and universal testing and treatment was feasible in an urban abortion clinic.
- Published
- 2021
- Full Text
- View/download PDF